Navigation Links
BioVex Closes Second Round of Series E Financing
Date:11/15/2007

Second and Final Close Completes $35 Million Financing

WOBURN, Mass., Nov. 15 /PRNewswire/ -- BioVex Inc, a clinical stage company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today it had completed its Series E financing, concurrent with the completion of a venture debt transaction, raising a total of $35m of funds.

BioVex intends to use the capital to complete its preparations for, and to commence, a Phase III study with its lead product OncoVex GM-CSF for the treatment of melanoma as well as to complete studies in head and neck cancer and pancreatic cancer. The financing will also fund the Company's second program, ImmunoVEX HSV2, a vaccine for genital herpes, through to Phase II.

The Series E placement was led by Triathlon Medical Ventures who were joined by new investors New Science Ventures and Harris and Harris Group, Inc., as well as existing investors. The venture debt facility was provided by Oxford Finance Corporation and Silicon Valley Bank.

About BioVex

BioVex is a privately held biotechnology Company based in Woburn. MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

BioVex's lead cancer program, OncoVEX GM-CSF, is an oncolytic virus that selectively destroys tumor cells accompanied by the induction of a systemic immune response. OncoVEX GM-CSF is currently completing a Phase II clinical trial for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Preliminary data from these studies has been very encouraging demonstrating OncoVEX GM-CSF has the potential to treat both local and metastatic disease. The Company is currently preparing for an initial registration study in melanoma where multiple responses have been demonstrated in an ongoing Phase II trial testing OncoVEX GM-CSF as stand alone therapy in patients with un-resectab
'/>"/>

SOURCE BioVex Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Scientists at NYU Langone Medical Center have ... of the process for turning adult cells into so-called ... vitamin C. Using the new technique in mice, the ... adult skin cells by more than 20-fold compared with ... and reliable, and thus should generally accelerate research aimed ...
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics ... from preclinical studies characterizing the analgesic profiles of ... kappa opioid receptor agonist molecules. The preclinical research ... medicinal chemistry platform. The analgesic properties ... the medical literature. 1,2 Kappa opioid receptors ...
(Date:9/19/2014)... Dublin ... announced the addition of the  "Micro Market Monitor ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... fastest-growing segments in the chromatography market. The market ... expected to reach $2.0 billion by 2019, at ...
(Date:9/18/2014)... , Sept. 18, 2014 About ... testing, is performed outside a clinical laboratory. It ... in administrating appropriate treatments and medication. POCT is ... prevalence of lifestyle diseases such as diabetes, heart ... user-friendly. POCT devices are standardized to minimize errors ...
Breaking Biology Technology:NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2
... New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge -- OXFORD, England, October 21, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
... ACCESS PHARMACEUTICALS, INC. (OTC ... leveraging its proprietary drug-delivery platforms to develop treatments in ... it has submitted additional patent applications, covering its Cobalamin-mediated ... injectable drugs, as a result of the growing interest ...
... HONG KONG, Oct. 20 /PRNewswire-Asia-FirstCall/ -- ... ... lpUnit=,PRN,; --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
Cached Biology Technology:A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 2A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 3A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 4A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 5A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 6A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 7A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 8A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 9Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 3China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 2China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 3China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 4China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 5China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 6China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 7China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 8
(Date:9/19/2014)... professor will study multifunctional and specialized spinal cord ... National Science Foundation grant in the amount of ... professor in the Department of Biology, OU College ... differences between the multifunctional and specialized spinal cord ... and what connections they make. Berkowitz will ...
(Date:9/18/2014)... - Washington State University researchers have developed a unique ... power waste cleanup in rural areas. , The ... an inexpensive and quick way to clean up waste ... while reducing pollution. , Professor Haluk Beyenal and ... Engineering and Architecture discuss the system in the online ...
(Date:9/18/2014)... A novel robotic system that can operate inside the ... as part of a biomedical research partnership program at ... of determining if the robot, in conjunction with real-time ... accurate, less costly, and less discomforting for the patient. ... prostate cancer therapies with greater precision. , Developed by ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
... resources at the U.S. Department of Energy,s (DOE) ... how proteins misfold to create the tissue-damaging structures ... called amyloid fibrils, are also implicated in neurodegenerative ... prion diseases like Creutzfeldt-Jacob and mad cow disease., ...
... to KATC Channel 3 in Lafayette, LA on December 17, ... around Acadiana (the mostly French region of Louisiana in the ... instead controlled-sugar cane burns. But some residents living near the ... comfort. From a distance, these fires look like an ...
... trichopoda , a sprawling shrub that grows on just a ... plant in its family and genus. It is also one ... about 200 million years ago. Now, researchers from Indiana University, ... JGI), Penn State University, and the Institute of Research for ...
Cached Biology News:A wrong molecular turn leads down the path to Type 2 diabetes 2A wrong molecular turn leads down the path to Type 2 diabetes 3A gluttonous plant reveals how its cellular power plant devours foreign DNA 2A gluttonous plant reveals how its cellular power plant devours foreign DNA 3
... Immulon 2HB ELISA ... provide increased binding affinity for hydrophilic ... bottom works well for reagent injection ... Each strip accomodates ...
... The MX80 Series of positioning slides ... motor, ballscrew, leadscrew, micrometer, and manual. ... high performance, cost-effective multi-axis systems. These ... bearings, encoder resolutions down to 10 ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Biology Products: